Baird Financial Group
RPRX icon

Baird Financial Group’s Royalty Pharma RPRX Stock Holding History

Baird Financial Group’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.01M Sell
18,053
-1,947
-10% -$101K ﹤0.01% 1322
2026
Q1 		$959K Sell
20,000
-11,775
-37% -$516K ﹤0.01% 1266
2025
Q4 		$1.23M Sell
31,775
-3,225
-9% -$123K ﹤0.01% 1183
2025
Q3 		$1.23M Sell
35,000
-4,926
-12% -$178K ﹤0.01% 1196
2025
Q2 		$1.44M Sell
39,926
-11,255
-22% -$373K ﹤0.01% 1112
2025
Q1 		$1.59M Sell
51,181
-11,010
-18% -$349K ﹤0.01% 1032
2024
Q4 		$1.59M Buy
+62,191
New +$1.65M ﹤0.01% 1036
2022
Q4 		– Sell
-190,791
Closed -$7.67M – 1757
2022
Q3 		$7.67M Sell
190,791
-4,142
-2% -$177K 0.02% 467
2022
Q2 		$8.2M Sell
194,933
-4,500
-2% -$184K 0.02% 470
2022
Q1 		$7.77M Sell
199,433
-15,625
-7% -$614K 0.02% 503
2021
Q4 		$8.57M Hold
215,058
– – 0.02% 479
2021
Q3 		$7.77M Buy
+215,058
New +$8.36M 0.02% 482

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Baird Financial Group's RPRX Position: Q2 2026 in Review

Baird Financial Group reduced its Royalty Pharma (RPRX) stake by 9.7% in Q2 2026, selling an estimated $101K and leaving 18,053 shares worth $1.01M. The position accounts for ﹤0.01% of the portfolio, ranked #1322.

Baird Financial Group first reported a position in RPRX in Q3 2021 and has held it in 12 quarters since. The position peaked at $8.57M in Q4 2021. 645 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • Baird Financial Group held 18,053 shares of Royalty Pharma worth $1.01M as of Q2 2026.
  • Baird Financial Group sold 1,947 Royalty Pharma shares in Q2 2026, an estimated $101K.
  • Royalty Pharma made up ﹤0.01% of Baird Financial Group's portfolio in Q2 2026, its #1322 holding.
  • Baird Financial Group first reported a position in Royalty Pharma in Q3 2021 and has held it in 12 quarters since.
  • Baird Financial Group's Royalty Pharma position peaked at $8.57M in Q4 2021.
  • 645 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Baird Financial Group's 13F filing for Q2 2026, filed 12 Aug 2026.